Boundless Bio, Inc. earnings releases BOLD

Annual Quarterly

Boundless Bio, Inc. last reported quarterly results on May 8, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): diluted EPS of -$0.60. It usually reports 36–68 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–68 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 8, 2026 38 days after quarter end	Q1 FY2026 ended Mar 31, 2026	—	-14 +14.0%	-0.60 +15.5%
Mar 9, 2026 68 days after quarter end	Q4 FY2025 ended Dec 31, 2025	—	-13 +21.7%	-0.58 +22.1%
Nov 5, 2025 36 days after quarter end	Q3 FY2025 ended Sep 30, 2025	—	-14 +15.9%	-0.62 +16.2%
Aug 5, 2025 36 days after quarter end	Q2 FY2025 ended Jun 30, 2025	—	-16 +7.7%	-0.70 +9.1%
May 9, 2025 39 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-16 -2.1%	-0.71 +94.2%
Nov 7, 2024 38 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-17	-0.74
Aug 12, 2024 43 days after quarter end	— ended Jun 30, 2024	—	—	—
May 13, 2024 43 days after quarter end	— ended Mar 31, 2024	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BOLD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: La Jolla, CA
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1782303

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.